Akshay Vaishnaw - Editas Medicine Director
| EDIT Stock | USD 5.60 0.11 2.00% |
Director
Dr. Akshay K. Vaishnaw is Independent Director of the Company. Dr. Vaishnaw has served as a member of our Board since July 2016. Dr. Vaishnaw has served as the President, Research and Development of Alnylam Pharmaceuticals, Inc., which develops RNAbased therapies, since March 2018. Prior to that, Dr. Vaishnaw held a variety of positions at Alnylam, including Executive Vice President, Research and Development from December 2014 until March 2018, Chief Medical Officer from June 2011 until December 2016, Executive Vice President from June 2012 to December 2014, Senior Vice President from June 2011 to June 2012, Senior Vice President, Clinical Research from December 2008 to June 2011 and Vice President, Clinical Research from 2006 to 2008. From December 2014 until July 2018, Dr. Vaishnaw served as a director of Visterra, Inc., a private biopharmaceutical company focused on antibodybased therapies. From 1998 to 2005, Dr. Vaishnaw held various positions at Biogen since 2016.
| Age | 55 |
| Tenure | 8 years |
| Professional Marks | Ph.D |
| Address | 11 Hurley Street, Cambridge, MA, United States, 02141 |
| Phone | 617 401 9000 |
| Web | https://www.editasmedicine.com |
Akshay Vaishnaw Latest Insider Activity
Tracking and analyzing the buying and selling activities of Akshay Vaishnaw against Editas Medicine stock is an integral part of due diligence when investing in Editas Medicine. Akshay Vaishnaw insider activity provides valuable insight into whether Editas Medicine is net buyers or sellers over its current business cycle. Note, Editas Medicine insiders must abide by specific rules, including filing SEC forms every time they buy or sell Editas Medicine'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Akshay Vaishnaw few days ago Acquisition by Akshay Vaishnaw of 36000 shares of Scholar Rock at 9.11 subject to Rule 16b-3 | ||
Akshay Vaishnaw over six months ago Acquisition by Akshay Vaishnaw of 5082 shares of Alnylam Pharmaceuticals subject to Rule 16b-3 | ||
Akshay Vaishnaw over six months ago Exercise or conversion by Akshay Vaishnaw of 30913 shares of Alnylam Pharmaceuticals subject to Rule 16b-3 | ||
Akshay Vaishnaw over six months ago Acquisition by Akshay Vaishnaw of 5312 shares of Alnylam Pharmaceuticals subject to Rule 16b-3 |
Editas Medicine Management Efficiency
The company has return on total asset (ROA) of (0.2087) % which means that it has lost $0.2087 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4317) %, meaning that it created substantial loss on money invested by shareholders. Editas Medicine's management efficiency ratios could be used to measure how well Editas Medicine manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.32 in 2024. Return On Capital Employed is likely to drop to -0.41 in 2024. Non Current Liabilities Total is likely to gain to about 115.2 M in 2024, whereas Total Current Liabilities is likely to drop slightly above 40.9 M in 2024.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Sangeeta Bhatia | Vertex Pharmaceuticals | 49 | |
| Paul Amatavivadhana | Ginkgo Bioworks Holdings | N/A | |
| David Bonderman | Allogene Therapeutics | 75 | |
| Alan Garber | Vertex Pharmaceuticals | 62 | |
| Jim Kasinger | Crispr Therapeutics AG | N/A | |
| Ali Behbahani | Crispr Therapeutics AG | 40 | |
| JeanFrancois Formela | Intellia Therapeutics | 61 | |
| John DeYoung | Allogene Therapeutics | 55 | |
| William Young | Vertex Pharmaceuticals | 73 | |
| Fred Cohen | Intellia Therapeutics | 61 | |
| Joshua Kazam | Allogene Therapeutics | 47 | |
| Carl Gordon | Intellia Therapeutics | 52 | |
| David Greenway | Vertex Pharmaceuticals | 34 | |
| Pablo Cagnoni | Crispr Therapeutics AG | 55 | |
| Chaloemphong Mahawanitwong | Ginkgo Bioworks Holdings | 42 | |
| Thomas Woiwode | Crispr Therapeutics AG | 44 | |
| Suchet Sunthorawet | Ginkgo Bioworks Holdings | 48 | |
| Chathaphum Khantiwiriya | Ginkgo Bioworks Holdings | 52 | |
| Frank Verwiel | Intellia Therapeutics | 55 | |
| Suphaphorn Chuasiriphatthana | Ginkgo Bioworks Holdings | 45 | |
| Sirisak Piyathatsikun | Ginkgo Bioworks Holdings | 42 | |
Management Performance
| Return On Equity | -0.43 | ||||
| Return On Asset | -0.21 |
Editas Medicine Leadership Team
Elected by the shareholders, the Editas Medicine's board of directors comprises two types of representatives: Editas Medicine inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Editas. The board's role is to monitor Editas Medicine's management team and ensure that shareholders' interests are well served. Editas Medicine's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Editas Medicine's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Kevin Bitterman, Independent Director | ||
| Alexandra Glucksmann, COO | ||
| John Mendlein, Independent Director | ||
| Boris Nikolic, Independent Director | ||
| Vickesh Myer, CTO | ||
| Douglas Cole, Independent Director | ||
| Andrew Hirsch, Director | ||
| Gilmore MD, CEO President | ||
| Alexis Borisy, Independent Director | ||
| Gerald Cox, Chief Medical Officer | ||
| Gilmore ONeill, CEO President | ||
| James Mullen, Chairman of the Board | ||
| Mark Mullikin, Investor Relations Officer | ||
| Michelle Robertson, Principal CFO | ||
| Harry III, VP Operations | ||
| Eric Ek, Interim CFO, Principal Accounting Officer and Principal Financial Officer | ||
| Baisong MD, Senior Officer | ||
| Andrew Hack, CFO | ||
| Jessica Hopfield, Director | ||
| Linda Burkly, Executive Officer | ||
| Cynthia Collins, Director | ||
| Katrine Bosley, President CEO, Director | ||
| Doug Cole, Independent Director | ||
| Akshay Vaishnaw, Director | ||
| Charles Albright, Chief Scientific Officer | ||
| David Scadden, Director | ||
| Bruce Eaton, Exec Officer | ||
| Cristi Barnett, Corporate Relations | ||
| Charlene JD, Executive Counsel | ||
| David Liu, CoFounder Member | ||
| Mark Shearman, Ex Officer | ||
| Feng Zhang, CoFounder Member | ||
| Linea Aspesi, Executive Officer | ||
| CPA CFA, CFO VP | ||
| George Church, CoFounder Member |
Editas Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Editas Medicine a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.43 | ||||
| Return On Asset | -0.21 | ||||
| Profit Margin | (1.96) % | ||||
| Operating Margin | (0.40) % | ||||
| Current Valuation | 162.58 M | ||||
| Shares Outstanding | 82.23 M | ||||
| Shares Owned By Insiders | 0.30 % | ||||
| Shares Owned By Institutions | 80.01 % | ||||
| Number Of Shares Shorted | 16.36 M | ||||
| Price To Earning | (7.02) X |
Editas Medicine Investors Sentiment
The influence of Editas Medicine's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Editas. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Editas Medicine's public news can be used to forecast risks associated with an investment in Editas. The trend in average sentiment can be used to explain how an investor holding Editas can time the market purely based on public headlines and social activities around Editas Medicine. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Editas Medicine's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Editas Medicine's and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Editas Medicine's news discussions. The higher the estimated score, the more favorable is the investor's outlook on Editas Medicine.
Editas Medicine Implied Volatility | 91.89 |
Editas Medicine's implied volatility exposes the market's sentiment of Editas Medicine stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Editas Medicine's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Editas Medicine stock will not fluctuate a lot when Editas Medicine's options are near their expiration.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Editas Medicine in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Editas Medicine's short interest history, or implied volatility extrapolated from Editas Medicine options trading.
Pair Trading with Editas Medicine
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Editas Medicine position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Editas Medicine will appreciate offsetting losses from the drop in the long position's value.Moving together with Editas Stock
| 0.65 | EGRX | Eagle Pharmaceuticals | PairCorr |
| 0.79 | JNJ | Johnson Johnson Aggressive Push | PairCorr |
Moving against Editas Stock
| 0.52 | ELYM | Eliem Therapeutics | PairCorr |
The ability to find closely correlated positions to Editas Medicine could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Editas Medicine when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Editas Medicine - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Editas Medicine to buy it.
The correlation of Editas Medicine is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Editas Medicine moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Editas Medicine moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Editas Medicine can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Editas Medicine. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product. For more information on how to buy Editas Stock please use our How to Invest in Editas Medicine guide.You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.
Complementary Tools for Editas Stock analysis
When running Editas Medicine's price analysis, check to measure Editas Medicine's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Editas Medicine is operating at the current time. Most of Editas Medicine's value examination focuses on studying past and present price action to predict the probability of Editas Medicine's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Editas Medicine's price. Additionally, you may evaluate how the addition of Editas Medicine to your portfolios can decrease your overall portfolio volatility.
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins |
Is Editas Medicine's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Editas Medicine. If investors know Editas will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Editas Medicine listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.02) | Revenue Per Share 1.028 | Quarterly Revenue Growth 8.187 | Return On Assets (0.21) | Return On Equity (0.43) |
The market value of Editas Medicine is measured differently than its book value, which is the value of Editas that is recorded on the company's balance sheet. Investors also form their own opinion of Editas Medicine's value that differs from its market value or its book value, called intrinsic value, which is Editas Medicine's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Editas Medicine's market value can be influenced by many factors that don't directly affect Editas Medicine's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Editas Medicine's value and its price as these two are different measures arrived at by different means. Investors typically determine if Editas Medicine is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Editas Medicine's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.